State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Publication Title
Current opinion in obstetrics & gynecology
Document Type
Article
Publication Date
4-1-2025
Keywords
Humans; Female; Endometrial Neoplasms; Antineoplastic Agents, Hormonal; Fertility Preservation; Selective Estrogen Receptor Modulators; Medroxyprogesterone Acetate; Aromatase Inhibitors; Neoplasm Recurrence, Local; Receptors, Progesterone; Megestrol Acetate; washington; swedish; swedish cancer
Abstract
PURPOSE OF REVIEW: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.
RECENT FINDINGS: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks. Biomarkers, including progesterone receptor status and molecular subtyping, are improving patient selection and outcomes. In advanced EC, single-agent and combination endocrine therapies with agents like selective estrogen receptor modulators, selective estrogen receptor down-regulators (SERDs), and aromatase inhibitors show efficacy, especially in hormone receptor-positive disease. Newer agents, including next-generation SERDs and proteolysis-targeting chimeras, hold potential for treating resistant cases.
SUMMARY: Endocrine therapy offers a well tolerated alternative to chemotherapy in selected EC patients, particularly those with hormone-sensitive tumors. Advances in molecular profiling and the development of novel endocrine agents are refining treatment strategies, supporting endocrine therapy's continued role in managing EC across various stages.
Area of Special Interest
Cancer
Area of Special Interest
Women & Children
Specialty/Research Institute
Oncology
Specialty/Research Institute
Obstetrics & Gynecology
DOI
10.1097/GCO.0000000000001008
